Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
Complete metastasectomy (CM) in metastatic renal cell carcinoma (mRCC) has demonstrated efficacy in the cytokine era, but its effectiveness in the era of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) remains unclear. A multi-institutional database included clinicopathological data of 367 patients with mRCC. Patients were divided into two groups: the CM group and the non-CM group. These two groups were compared before and after propensity score matching (PSM). Cox proportional hazard models were used to detect factors associated with disease-free survival (DFS) and overall survival (OS) from mRCC diagnosis. The CM group showed a significant association with longer overall survival compared to the non-CM group in the PSM-unadjusted cohorts (p < 0.001, hazard ratio 0.49, 95% confidence interval 0.35-0.69), but no superiority was noted in the adjusted cohorts. The median DFS after CM was 24 months, with no significant differences based on relapse timing. Notably, the international metastatic RCC database consortium risk categories and metastatic burden were associated with DFS. This study supports the potential of CM in mRCC management during the TKI/ICI era, although limitations including sample size and selection bias need to be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Cancers - 16(2024), 4 vom: 19. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shimizu, Takuto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immune checkpoint inhibitor |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers16040841 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368882144 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368882144 | ||
| 003 | DE-627 | ||
| 005 | 20240229164701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers16040841 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM368882144 | ||
| 035 | |a (NLM)38398232 | ||
| 035 | |a (PII)841 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shimizu, Takuto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Complete metastasectomy (CM) in metastatic renal cell carcinoma (mRCC) has demonstrated efficacy in the cytokine era, but its effectiveness in the era of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) remains unclear. A multi-institutional database included clinicopathological data of 367 patients with mRCC. Patients were divided into two groups: the CM group and the non-CM group. These two groups were compared before and after propensity score matching (PSM). Cox proportional hazard models were used to detect factors associated with disease-free survival (DFS) and overall survival (OS) from mRCC diagnosis. The CM group showed a significant association with longer overall survival compared to the non-CM group in the PSM-unadjusted cohorts (p < 0.001, hazard ratio 0.49, 95% confidence interval 0.35-0.69), but no superiority was noted in the adjusted cohorts. The median DFS after CM was 24 months, with no significant differences based on relapse timing. Notably, the international metastatic RCC database consortium risk categories and metastatic burden were associated with DFS. This study supports the potential of CM in mRCC management during the TKI/ICI era, although limitations including sample size and selection bias need to be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a metastasectomy | |
| 650 | 4 | |a renal cell carcinoma | |
| 650 | 4 | |a tyrosine kinase inhibitor | |
| 700 | 1 | |a Miyake, Makito |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Nobutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Itami, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Tachibana, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Omori, Chihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Oda, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kohashi, Mikiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tomizawa, Mitsuru |e verfasserin |4 aut | |
| 700 | 1 | |a Onishi, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Hori, Shunta |e verfasserin |4 aut | |
| 700 | 1 | |a Morizawa, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Dotoh, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakai, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Torimoto, Kazumasa |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Nobumichi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Kiyohide |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 16(2024), 4 vom: 19. Feb. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:4 |g day:19 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers16040841 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 4 |b 19 |c 02 | ||